P/E ratio for Can Fite Biopharma (CANF)
P/E ratio as of April 2024 (TTM): -0.6972
According to Can Fite Biopharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.697221. At the end of 2022 the company had a P/E ratio of -2.03.
P/E ratio history for Can Fite Biopharma from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.03 | 41.86% |
| 2021 | -1.43 | 8.79% |
| 2020 | -1.32 | 50.11% |
| 2019 | -0.8777 | -76.32% |
| 2018 | -3.71 | -4.85% |
| 2017 | -3.89 | -1.81% |
| 2016 | -3.97 | -43.63% |
| 2015 | -7.04 | 39.4% |
| 2014 | -5.05 | 10.82% |
| 2013 | -4.55 | 454.71% |
| 2012 | -0.8211 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.